“The Evidence and Clinical Rationale for the Use of JAK Inhibitors in the Management of AD ”. Canadian Allergy & Immunology Today, vol. 2, no. s11, Nov. 2022, pp. 3–11, https://doi.org/10.58931/cait.2022.2s1148.